ERBB2 and breast carcinoma: DESTINY-Breast15 is a phase IIIB trial further evaluating the activity of T-DXd in patients with advanced HER2-low or HER2 IHC score 0 breast cancer, including hormone receptor-negative (i.e. TNBC) tumors (NCT05950945).